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Abstract
High-throughput RNA sequencing enables quantification of transcripts (both known and novel), exon/exon junctions and
fusions of exons from different genes. Discovery of gene fusions–particularly those expressed with low abundance– is a
challenge with short- and medium-length sequencing reads. To address this challenge, we implemented an RNA-Seq
mapping pipeline within the LifeScope software. We introduced new features including filter and junction mapping,
annotation-aided pairing rescue and accurate mapping quality values. We combined this pipeline with a Suffix Array Spliced
Read (SASR) aligner to detect chimeric transcripts. Performing paired-end RNA-Seq of the breast cancer cell line MCF-7 using
the SOLiD system, we called 40 gene fusions among over 120,000 splicing junctions. We validated 36 of these 40 fusions
with TaqMan assays, of which 25 were expressed in MCF-7 but not the Human Brain Reference. An intra-chromosomal gene
fusion involving the estrogen receptor alpha gene ESR1, and another involving the RPS6KB1 (Ribosomal protein S6 kinase
beta-1) were recurrently expressed in a number of breast tumor cell lines and a clinical tumor sample.
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Introduction
The transcriptome comprises the set of all transcripts in a cell and
their quantity at a specific stage and time. RNA-Seq enables
hypothesis-neutral investigation of the expression of the transcripts
including non-coding RNA and viruses [1]. RNA-Seq provides
advantages over microarray technology such as the detection of
novel transcripts (both truly novel as well as those arising from
alternative splicing) and sensitivity over a greater range of
expression [2]. Methods to more comprehensively analyze RNA
sequencing data are being developed, with particular focus on
normalization of differential gene expression, annotation of the
transcriptome,and characterizationof the splicing junctions [3–12].
Paired-end RNA-Seq further enhances quantification of alternative
transcripts [13–16]. Analysis of tissue and single-cell-specific RNAis
revealing cellular gene expression diversity and phenotypy [17–19].
Gene fusions arise from mutations including translocations,
deletions, inversions, or trans-splicing. Fusion genes are thought to
cause tumorigenesis by over-activating proto-oncogenes, deacti-
vating tumor suppressors, or altering the regulation and/or
splicing of other genes which lead to defects in key signaling
pathways [20]. Fused RNAs are found to occur in significantly
higher frequency in cancer than in matched benign samples and
may be potential biomarkers [21]. For example, 95% of patients
with clinical chronic myeloid leukemia (CML) express the BCR-
ABL gene fusion in their leukemia cells due to a reciprocal
translocation between the long arms of chromosomes 9 and 22
[22,23]. BCR-ABL is also found to be a factor in 30% to 50% of
adult acute lymphoblastic leukemia cases [24]. Imatinib is a
specific tyrosine kinase inhibitor targeting BCR-ABL and is an
effective treatment for CML [25,26]. Gene fusions are also
detected repeatedly in other tumors. Examples include ETV6-
NTRK3 in mesoblastic nephroma, congenital fibrosarcoma, and
breast carcinoma [27–29]. MYB-NFIB in head and neck tumors
[30], TMPRSS2-ERG/ETS in prostate cancer [31–34], and
EML4-ALK in lung cancer [33,35]. Most lung tumors with ALK
rearrangements are shown to shrink and stabilize when patients
are given the ALK inhibitor Crizotinib [36].
Hypothesis-neutral gene fusion detection with RNA-Seq was
recently demonstrated by different groups [37–46]. For example,
the FusionSeq software uses paired-end reads to find candidate
fusions, and applies a set of filtration modules to remove false
positive candidates [41]. FusionSeq applies misalignment filters for
large- and small-scale homology, low complexity repetitive
regions, and mitochondrial genes particularly considering reads
that fall on SNP regions or on RNA edited transcripts that may
cause misalignments. deFuse guides a dynamic programming
based spliced read detection module with paired-end alignments
[42]. Both of these methods reply upon paired-end alignments as
the initial evidence and apply spliced read mapping on the
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the whole genome first and then guiding them with paired-end
alignments [38].
In this study, we describe a new method which considers
spliced-read and paired-end alignments independently from each
other, enabling detection of fusions from single fragment or
paired-end experiments. We also introduce techniques for
mapping of spliced-reads to a suffix array based virtual gene
fusion reference with annotation-aided pairing rescue and
methods for quality assessment of alignments and splice junctions.
We tested our analysis tool by calling the exon/exon junctions and
gene fusions from data generated by sequencing three paired-end
RNA-Seq libraries, each with two technical replicates. We also
compared our results to TopHat and FusionSeq software on the
MCF-7 sample. Next we validated candidate MCF-7 gene fusions
using TaqManH assays and showed that 90% of the calls were
valid and over 65% were specific to MCF-7. We also identified
what appears to be an early breakpoint bias at the 59 fused genes.
Finally, we surveyed a subset of MCF-7 and UHR fusions on a
panel of breast cancer cell lines and discovered evidence for
recurrence.
Results
A combined strategy to detect splice junctions and
fusion breakpoints
We prepared strand-specific, paired-end RNA libraries from the
Universal Human Reference (UHR), the Human Brain Reference
(HBR), and the breast cancer cell line MCF-7 using the Total
RNA-Seq kit from Applied Biosystems. These RNA libraries were
sequenced using ligation-based high throughput SOLiD
TM system
[47]. Fragments were gel-selected for insert sizes between 100–200
base pairs (Figure S1 in Text S1). Using a new transcriptome
alignment pipeline in which each pair of reads is mapped to
genome, junction, exon and filter references and paired with a
pairing quality value (PQV), we obtained total of 580 million read
pairs that were confidently mapped to the human genome (Table
S1 in Text S2). Histograms of gene expression showed a wide
range of distribution, and average R
2 correlation of gene
expression between replicates ranged from 0.95 to 0.96 (Figures
S2, S3 in Text S1).
Splice junctions were discovered by combining three approach-
es: (1) BRIDGE evidence found by paired-end reads in which the
forward read maps on an exon and the reverse read maps on
another exon with a PQV above a confidence threshold; (2) SPAN
evidence found by single reads (of paired-end reads) in which the
read alignment spans the breakpoint of a set of known and
putative splice junctions; (3) Fusion SPAN evidence found by
fusion alignments spanning hypothetical breakpoints of any two
exons discovered using the SASR aligner which assesses all exon-
exon combinations in the genome (Figure 1). Using this strategy,
for each sample, we identified an average of 133,000 RefSeq and
15,315 non-RefSeq (putative) splice junctions and 5 to 56
candidate fusion breakpoints (Table 1 and Table S1 in Text S2).
To assess the performance of mapping quality values generated
with the system, we compared fold-change ratio (Log2 [UHR/
HBR]) of gene RPKM values with gene expression assays from the
MicroArray Quality Control (MAQC) project [48,49]. We
compared correlation of four different PQV (1, 10, 20 and 40)
thresholds with the assays (Figure S4 in Text S1). Pearson
correlations of data from TaqMan assays with that of the data
from the SOLiD system were not significantly different between
PQV thresholds. The slope (m) of the regression fits, however, was
significantly affected by the threshold settings. As PQV is increased
from 1 to 40, the slope increased dramatically from 0.77 to 0.88,
indicating significantly greater accuracy compared to a ‘‘gold
standard’’ qPCR method. The increase in accuracy is likely a
result of increased specificity. Essentially, the log ratio dynamic
range increases with increasing PQV settings (Figure S5 in Text
S1). RPKM distributions show an increase in low-end signal for
lower PQV. If this increase in ‘‘sensitivity’’ represents additional
noise, it can contribute to a loss of accuracy in the fold change
calculations. The increase in the low end suggests that these reads
may be spurious (Figure S6 in Text S1).
Parameter stringency and quality assessment
In order to find optimal filters for detecting splice junctions with
our combined approach, we compared three quality thresholds
using data from the UHR and HBR barcoded libraries: (1) one
SPAN evidence (1-SR), (2) two unique SPAN evidences (2-SR),
and (3) one BRIDGE and one SPAN evidences (1-PE-1-SR). In
addition to these tested thresholds, we applied default filter of
choosing only primary alignments with PQV.10. The results, as
illustrated in Figure 2, suggest an increased number of false
positives for 1-SR evidence even though it may have greater
sensitivity. 1-PE-1-SR threshold reduced false positives especially
for fusions, generating less calls than 2-SR threshold. For the
analyses described later in the text, 1-PE-1-SR threshold was
chosen for calling splice junctions and 2-PE-2-SR for calling gene
fusions. On average, 82% of junctions identified in the libraries
were present in the RefSeq database. 84% of these known
junctions and 26% of the putative junctions were shared between
at least two of the three libraries (Figure S7 in Text S1). The
highest number of library-specific known junctions was observed
in HBR, and the highest number of library-specific putative
junctions was observed in MCF-7.
Next, we formulated a Junction Confidence Value (JCV) and
investigateditsutilitytoidentifytrueversusfalsejunctions.Detailsof
JCV and its formulation are explained in supplementary methods in
Text S1. One type of false positive fusion junction is likely called
between highly expressed exons for which the random chance of
encountering a misalignment or mispairing is elevated. Homology
between highly expressed genes would alsoincrease this type of false
positive. We created JCV to test the quantity and quality of
BRIDGE evidences when compared to an ‘error expectation
metric’. This metric is defined as the estimation of the null
hypothesis of encountering a random junction between the two
Author Summary
Advances in sequencing technology are enabling detailed
characterization of RNA transcripts from biological sam-
ples. The fundamental challenge of accurately mapping
the reads on transcripts and gleaning biological meaning
from the data remains. One class of transcripts, gene
fusions, is particularly important in cancer. Some gene
fusions are prominent markers in leukemia, prostate, and
other cancers and putatively causative in certain tumor
types. We present a set of new RNA-Seq analysis
techniques to map reads, and count expression of genes,
exons and splicing junctions, especially those that give
evidence of gene fusions. These tools are available in a
software package with a straightforward graphical user
interface. Using this software, we called and validated
several gene fusions in a breast cancer cell line. By testing
the presence of these fusions in a larger population of
tumor cell lines and clinical samples, we found that two of
them were expressed recurrently.
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which was predictive of the false discovery rate and at the same time
distinguished significant number of novel junctions to either lower
or higher score bins (Figure 3A). Known/putative ratios ranged
from 0.15 for JCV cutoff of 0; 3 for JCV cutoff of 50 and 16 for JCV
cutoff of 100. In order to test the sensitivity of JCV, we simulated
1,000,000 junctions based on a combination parameter model of
true junction expression ratio and false junction misalignment ratio.
True positive rate (TPR) and false positive rate (FPR) were
calculated by comparing whether a called junction was real (Figures
S8, S9, S10 in Text S1). These simulations showed that JCV was
predictive of true junction calls and higher JCV thresholds resulted
in much less FPR and slightly less TPR. We performed a separate
simulation of gene fusion detection using reads from a DH10B
(E.coli) DNA sequencing experiment where introns, exons and a
gene model were simulated to make the data similar to RNA-Seq
experiments. Our algorithm was able to detect 86 out of 93
simulated fusions in this experiment (Figure S11 in Text S1).
Figure 1. RNA-Seq mapping and splice junction detection methodology. A. Four reads that span (spliced single reads), and three reads that
bridge (paired-end reads) the junction are shown. The top chart shows a bird’s eye view of the genomic alignments detected for seven pairs of reads
between the two exons. Areas of the read highlighted in red correspond to colors that do not align to a genomic reference, and dots in the reference
are unknown colors/bases. B. Mapping pipeline is reviewed in the Methods sections. Candidate junctions correspond to a sparse graph of junction
evidences. After the candidates are found, splice junction and fusion predictions are made with optional quality thresholds. C. As a first step in SASR,
10 to 35 bp ends from each end of the exon are stored in two lexicographical dictionaries. Stored suffix starts are shown as a vertical stop and end
with empty triangles. D. 10 base pairs from the left and right ends of the read (decamers) are searched in the 39 and 59 end dictionaries, respectively,
with a binary string search. Decamers are matched without mismatches. Matching decamers are extended as possible (with up to two mismatches) to
determine whether they cover the entire suffix. Mismatches are illustrated as vertical lines. Up to ten bases are clipped from the ends of the reads
until a matching read is found. E. Decamer block size frequency in the hg18 RefSeq database.
doi:10.1371/journal.pcbi.1002464.g001
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default paired-end parameters for color space. TopHat reported
124,236,156 mapped reads of which 33,634,800 were properly
paired whereas LifeScope reported 404,901,929 mapped reads, of
which 300,341,259 pairs were mapped to the same chromosome
and 158,050,096 were properly paired (Table S1 in Text S2). Of
note, TopHat allows 2 mismatches on mapped reads by default
and does not report pairs of reads mapped across different
chromosomes. Next we identified appropriate score threshold for
calling TopHat junctions. For each junction found, TopHat
reports a score which corresponds to the number of reads that
span the junction. TopHat reported 1,391,319 total junctions
without any score filter and with score.5 threshold this number
reduced to 53,402 (Figure S12 in Text S1). We used TopHat
candidate junctions with score.5 for comparison to RefSeq
known and Lifescope candidate junctions (Figure 3B). There is
some evidence that score.10 may yield more specific results for
TopHat (Figure S12 in Text S1). Of note, known (RefSeq)
junctions called by TopHat dropped from 129,316 (score.0) to
106,962 (score.5). These results suggest that TopHat detects a
large number of putative novel junctions yet is not as sensitive
when distinguishing false positives. LifeScope detected 15,074
putative novel junctions between known exons of the same gene
that weren’t called by TopHat. We could distinguish that more
Table 1. Mapping and splicing statistics for paired-end runs.
Dataset #Confidently Aligned Pairs #Known Splice #Putative Splice #Putative Fusion
UHR-1 79,654,007 127,987 9,025 5
UHR-2 113,699,316 136,839 14,365 13
HBR-1 89,066,940 129,031 8,709 8
HBR-2 130,521,674 138,718 14,204 14
MCF-7-1 79,654,007 123,442 17,373 40
MCF-7-2 86,796,592 120,503 19,437 56
Notes: Confidently aligned pairs was defined as primary alignments with PQV.10. 120 and 150 refer to insert size of RNA library. MCF-7 and MCF-7 -2 libraries were
prepared separately from the same lot. Known splicing events are found in RefSeq database whereas putative splicing events were not.
doi:10.1371/journal.pcbi.1002464.t001
Figure 2. Combined evidence improves specificity of splice and
fusion detection. Scatterplots show the increasing mapped coverage
(x-axis) versus Left: Known RefSeq junctions; Middle: Putative junctions;
Right: Fusion junctions. Top track shows results for UHR and bottom
track for HBR. Three different evidence thresholds were compared: 1)
red line: one SPAN (SR) evidence required for junction call, 2) magenta
line: two SPAN (2-SR) evidences required for junction call, and 3) blue
line: one SPAN and one BRIDGE evidence (1-SR-1-PE) required for
junction call.
doi:10.1371/journal.pcbi.1002464.g002
Figure 3. Improvements by junction confidence value and
comparison to TopHat. A. Logarithms of number of known and
putative junctions are shown with yellow and blue bars respectively.
The ratio of known over putative is shown with dashed line. Dataset
consisted of 64,000 sample UHR junctions called with default
thresholds. B. TopHat and Lifescope candidate calls were compared
to each other and also to RefSeq database. TopHat junctions were
filtered with score.5, and Lifescope junctions were filtered with 1-SR-1-
PE threshold (requiring one span and one bridge evidence).
doi:10.1371/journal.pcbi.1002464.g003
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positives by looking at their JCV; 3,520 had JCV=0 and 8,481
had JCV=100 with the rest having scores between 0 and 100.
Detection and validation of fusion transcripts in the MCF-
7 cell line
Using the combined BRIDGE&SPAN approach described
above on the UHR sample, we called and validated previously
reported gene fusions including BCR-ABL1, GAS6-RASA3,
ARFGEF2-SULF2, NUP214-XKR3 and BAT3-SLC44A4
[37,39,40]. These fusions were not described in the literature for
HBR, and as expected were not identified in the HBR samples
sequenced. In MCF-7, a total of 40 putative fusions were identified
in the first sequencing run (50625 paired-end), of which 26 were
detected again in a second run (75635 paired-end) out of a total
56 fusion calls (Table S2 in Text S2). We also analyzed first MCF-
7 sequencing dataset using FusionSeq (Sboner et. al.). Six of the
forty gene fusions identified by LifeScope were also called by this
software. FusionSeq’s confidence value (RESPER) for these calls
ranged from 1.15 to 4.53. Of importance, the ribosomal filter and
single read validation module of FusionSeq (version 0.7) did not
handle color space data or data with different read length pairs
adding to 5807 total calls with RESPER.1 (Table S3 in Text S2).
Based on the calls from the first MCF-7 sequencing experiment,
we prepared 40 TaqMan fusion assays and run them on the UHR,
HBR, and MCF-7 samples along with the prostate cell line PC-3
as an additional control. 36 (90%) of the fusions were validated
with the assays and 25 (63%) were found to be specific to MCF-7
and UHR (Table 2 and Table S4 in Text S2). To note, 19 of these
‘‘specific’’ fusions were called with our algorithms in the second
run of MCF-7. JCV values correlated with whether a fusion was
called again, and also with the number of unique start points
(Figure S13 in Text S1).
Real-time PCR Cycle Threshold (CT) values showed that each
of the MCF-7 gene fusions was expressed in UHR with around
ten-fold less expression (Table 2). This suggests that MCF-7 or one
of its parent or sister cell lines is very likely part of the UHR pool.
According to the information provided by the supplier, UHR
RNA is prepared from a pool of ten different cancer cell lines, one
of which is an ‘adenocarinoma, mammary gland’. MCF-7 is an
adenocarcinoma cell line from mammary gland. From the RNA-
Seq calls, nine of the MCF-7 gene fusions were detectable in UHR
with ,200 million confidently mapped reads whereas these fusions
were detectable in MCF-7 with only ,80 million reads. It is likely
that deeper sequencing of the UHR pool would have identified the
remaining fusions.
Many MCF-7 fusions were between genes in three bands of Chr
1, Chr 17 and Chr 20 (Figure 4). These bands were previously
described as rearrangement ‘‘hot-spots’’ [50]. Of the total 11 inter-
chromosomal or inverted intra-chromosomal fusions, five had
premature stop codons (not in frame), while six were in frame.
Two of the fusions were alternatively spliced including the fusion
from the second exon of ESR1 to the sixth and seventh exon of
C6orf97, and the fusion from the first and second exon of
ADAMTS19 to the tenth exon of SLC27A6. We also found
several new intra-chromosomal gene fusions mostly between
adjacent or neighboring genes (Table S4 in Text S2).
We observed an enrichment of fusions for which the breakpoints
were in the first intron of a gene, a similar bias explained also in
Inaki et al., 2011. This pattern was not observed for the UHR and
HBR samples (Figure 5A–B). On average, first introns in the
RefSeq database (hg18) constitute 22% of a gene. We asked
whether the large intron size alone might explain the breakpoint
bias at the 59 introns. We used a parametric bootstrap approach to
test the hypothesis that gene fusions are more likely to occur
towards the 59 end of a gene; for example, after the first exon.
Assuming that the breakpoint was in the middle of the intron
following the fused exon, we considered breakpoints for 23 fusions
from Table 2 (omitting multiple splices for ESR1 and
ADAMTS19). We simulated 100,000 gene fusion locations in
these 23 genes from a uniform distribution within the gene. We
normalized the location of the real gene fusions by gene length
(defined as the distance between the start of the first exon and the
end of the last exon). We calculated the mean fusion location of the
23 genes, in the observed fusions and in the simulated fusions. In
the real fusions, the mean insert location was 0.2587 (26% of the
length of the gene, Figure 5C). In 100,000 simulated sets of 23
fusions, the mean was 0.5 and the standard deviation was 0.06.
Only three in 100,000 of the simulated sets of fusions had a value
less than 0.2587. Thus the observed location of the gene fusions is
statistically significantly biased towards the 59 end of the gene, with
a p-value estimated at 3610
25.
Survey of UHR and MCF-7 fusions in cell lines and clinical
tumor samples
To test recurrence, we selected 24 fusions from UHR and
MCF-7 and investigated their expression in 20 cancer cell line
samples (Figure 6). UHR fusions BCR-ABL1 and BAT3-
SLC44A4 were found expressed in the myelogenous leukemia
cell line K562 but with eightfold higher expression than in UHR.
GAS6-RASA3 fusion was expressed only in UHR. Most of the
fusions in MCF-7 were also expressed at a low level in the Du4475
cell line with a higher CT value (.35 for most cases). Both MCF-7
and Du4475 cell lines are traced to a 69/70-year old Caucasian
female from Georgetown, but contamination, mixing, mislabeling,
or differences in culturing may have caused the observed
expression.
Two of the intra-chromosomal gene fusions were expressed in
multiple samples: ESR1-C6ORF97 and RPS6KB1-TMEM49.
The first of these fusions, between the estrogen receptor alpha
gene ESR1 and its neighboring gene C6ORF97 on Chr 6 was
expressed in two other ER+ breast cancer cell lines in addition to
UHR, MCF-7, and Du4475. This fusion may have occurred due
to an inversion or rearrangement, as normally the ESR1 gene is
downstream of C6ORF97 on the genome (on the same strand,
128,831 base pairs apart); yet the fusion junction was observed to
be from the second exon of ESR1 to the sixth exon of C6ORF97,
in the reverse order of expected transcription. We noted that these
two genes were considerably expressed in MCF-7 (RPKM 16 and
46 average), though not expressed at all in HBR (RPKM,0.5),
and weakly expressed in UHR (RPKM 1 and 1.8). The second
recurring fusion, RPS6KB1-TMEM49, was found expressed in
four cancer cell lines including HCC2157 and HelaS3. We further
tested the presence of 24 candidate fusions in cDNA from 48
Clinical Samples of Normal and Breast Tumors (Origene). We
found ESR1-C6ORF97 expressed in one ER+ tumor, and none of
the other fusions were expressed.
Discussion
RNA-Seq allows interrogation of known and novel transcript
expression and discovery of gene fusions. We describe a new suffix
array algorithm to find fusion breakpoint spanning reads in a
hypothesis-neutral fashion. We combine this algorithm with a new
paired-end mapping approach to detect gene fusions sensitively
and reliably. Our mapping method works with a predefined set of
exon boundaries which is readily available for the human genome
from RefGene or Ensembl databases. To detect novel splicing sites
RNA-Seq Mapping and Detection of Gene Fusions
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expressed islands of reads with tools such as TopHat [8], and next
add the predicted novel exons to the gene model, prior to using
our tool. Other de novo assembly algorithms, as long as they
generate de novo exon boundaries, and mapped back to genome
coordinates, may also be used with our tool [51–54].
By sequencing and analyzing the MAQC samples UHR and
HBR, and the breast cancer cell line MCF-7, we validated 25 gene
fusions specific to MCF-7 and UHR. Of these, five were not in
frame and had premature stop codons. These fusions might still
deploy a negative constraint on the fused genes by increasing non-
sense mediated decay (NMD) [55]. In addition, several gene
fusions that occur at the genomic level might not have been
detected by messenger RNA sequencing (mRNA) because their
pre-cursor mRNAs would have been degraded by the NMD
mechanism. Such fusions may be identified by DNA-level
sequencing.
Of the 29 intra-chromosomal fusions called in MCF-7 in this
study, 12 were not described in investigated literature (Table S4 in
Text S2). Interestingly, most of the adjacent MCF-7 gene fusions
did not fit the standard definition of ‘‘read-through’’ since they did
not occur between last and first exons of the fused genes and in
some cases they occurred in inverse order of expected transcrip-
tion. This indicates that these fusions may had arisen due to trans-
splicing or structural mutations such as deletions or inversions.
These hypotheses may be tested by directly sequencing the DNA
from these regions.
By surveying cancer cell lines with TaqMan assays, we observed
that two of the MCF-7 fusions involving adjacent genes, ESR1-
C6ORF97 and RBS6KB1-TMEM49 were expressed recurrently.
Fusions of the ESR1 gene may disrupt estrogen signaling pathways
and thus events involving this gene may be significant. RBS6KB1-
VMP1 fusion was described as a recurrent event recently by
another group [45]. VMP1 is another name for TMEM49.
Amplification of the RPS6KB1 loci (Ribosomal protein S6 kinase
beta-1) was described in other breast cancers as an oncogene event
[56]. Still, it is possible these recurrent fusions arise only in
immortalized cell lines rather than being driver mutations. In fact,
the ESR1 fusion tested positive in only one of the 48 clinical breast
samples, while the RPS6KB1 fusion was not expressed in any of
them. Of interest, six of the fusions originated on the band 17q23,
which was previously identified as a common region of
amplification in cancer [57].
In many of the MCF-7 fusions, the first or early introns of the 59
genes harbored the gene fusion breakpoint. A similar pattern was
observed in prostate cancer: the complete exon-1 of TMPRSS2
was identified to fuse with ETV1 or ERG as one of the most
recurrent rearrangements [31]. Recent studies on prostate cancer
found extended breakpoints at the androgen receptor binding sites
possibly due to LINE-1-induced ORF or topoisomerase-II beta.
Table 2. Validated MCF-7 gene fusions and TaqMan expression ratios.
59 Gene Exon Chr 39 Gene Exon Chr Distance MCF-7 UHR HBR PC-3
ARFGEF2-1 20 SULF2-3 20 Inverted 20.6 24.2 40.0 39.7
SLC25A24-4 1 NBPF6-16 1 Inverted 23.9 27.9 40.0 40.0
USP31-1 16 CRYL1-4 13 Inter-chr 27.5 31.8 40.0 40.0
TBL1XR1-1 3 RGS17-2 6 Inter-chr 26.1 30.6 40.0 40.0
TAF4-1 20 BRIP1-5 17 Inter-chr 25.6 29.2 40.0 40.0
RPS6KB1-6 17 DIAPH3-30 13 Inter-chr 22.6 26.1 40.0 36.7
BCAS4-1 20 BCAS3-24 17 Inter-chr 21.3 25.3 40.0 40.0
AHCYL1-1 1 RAD51C-10 17 Inter-chr 31.0 34.8 40.0 40.0
ABCA5-4 17 PPP4R1L-4 20 Inter-chr 26.1 29.9 40.0 40.0
C16orf45-1 16 ABCC1-15 16 641567 25.3 29.2 40.0 40.0
C16orf62-8 16 IQCK-10 16 264613 26.7 30.5 40.0 40.0
CXorf15-1 X SYAP1-2 X 251362 29.1 32.7 40.0 40.0
MYO6-1 6 SENP6-15 6 270841 28.4 31.9 40.0 40.0
RPS6KB1-2 17 TMEM49-11 17 272316 24.4 28.4 40.0 39.8
SMARCA4-7 19 CARM1-2 19 281642 29.9 33.1 40.0 40.0
POP1-2 8 MATN2-15 8 286928 28.5 31.8 40.0 40.0
GATAD2B-1 1 NUP210L-28 1 2107321 28.3 32.4 40.0 40.0
ESR1-2 6 C6orf97-7 6 2116116 32.3 35.0 40.0 40.0
ESR1-2 6 C6orf97-6 6 2128831 25.2 29.1 40.0 40.0
DEPDC1B-7 5 ELOVL7-8 5 2118895 25.6 29.0 39.8 40.0
GCN1L1-2 12 MSI1-12 12 2157216 25.3 28.2 40.0 39.8
ATXN7L3-1 17 FAM171A2-4 17 2158568 24.8 28.3 40.0 40.0
SYTL2-1 11 PICALM-20 11 2217187 26.7 30.7 40.0 40.0
ADAMTS19-1 5 SLC27A6-10 5 2432137 26.5 31.3 40.0 40.0
ADAMTS19-2 5 SLC27A6-10 5 2433412 25.8 30.5 40.0 40.0
Notes: Each exon name (gene name-dash-exon-order) was obtained from RefSeq database. Inverted fusions are on same chromosome but different strands. Last four
columns show the Cycle Threshold (CT) value in TaqMan assays. Lower CT values indicate higher expression.
doi:10.1371/journal.pcbi.1002464.t002
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were linked to increased chromosomal translocations of the
TMPRSS2, ETV1, and ERG genes [58,59]. Presence of the
early 59 breakpoints in MCF-7 genes suggest that recurrent
Figure 4. Localization of gene fusions on specific chromosomal regions. A. Whole genome and B. Chr 1, 17 and 20 gene fusions circular
graph. Red lines represent inter-chromosomal gene fusions, blue lines represent inverted intra-chromosomal and black lines represent same-strand
intra-chromosomal fusion events. Graphs were drawn with Circos software [61].
doi:10.1371/journal.pcbi.1002464.g004
Figure 5. Fusion breakpoints are biased to 59 end of the genes.
Histogram of order of 59 (yellow) and 39 (green) intron breakpoints for
A. MCF-7, B. UHR and HBR combined gene fusions. Breakpoint is
inferred to happen at the intron (X axis) following the exon that is
fused. Y axis shows the count of breakpoints that are inferred to
happen at numbered intron. C. Boxplot of the distribution of simulated
gene fusion locations for each of the 23 genes in which a fusion was
observed. Magenta star marks the location of the observed fusion,
relative to the 59 exon. 23 fusions correspond to the gene fusions from
Table 2 (except for ESR1- C6orf97, and ADAMTS19- SLC27A6 alternatively
spliced fusions merged into single data points).
doi:10.1371/journal.pcbi.1002464.g005
Figure 6. Screening of fusion assays in cancer cell lines reveal
recurring fusions. Heat map of the expression of selected gene
fusions (rows) in 20 samples including 18 cancer cell lines (columns).
Lower cycle threshold (CT) indicates a higher level of expression and is
highlighted in blue. High CT (max 40, yellow) indicates no expression.
PPIA is used as positive control and non template control sample (NTC)
as negative control.
doi:10.1371/journal.pcbi.1002464.g006
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promoter and early splicing sites due to factors not mediated by
the androgen receptor.
In conclusion, we presented a novel method of splice and fusion
detection from RNA-Seq data. We sequenced MCF-7, UHR and
HBR, and demonstrated high specificity in finding splices and
fusions de novo. We further showed that two of the MCF-7 gene
fusions are expressed recurrently in a number of tumor cell lines.
Materials and Methods
The instruments and reagents used in this study are for research
use only and not intended for diagnostic procedures. Additional
methods are provided at Supplementary Information Online.
RNA-Seq alignment pipeline
Reads were aligned to a reference using the Mapreads module
of the BioScope 1.3 and LifeScope 2.0 software (http://www.
lifetechnologies.com/lifescope). Four fasta references were used for
increased throughput and accuracy: (1) genomic reference, (2)
junction reference, (3) exon reference, and (4) filter reference
(Figure 1B). Filter reference contained polyA, polyC, polyG,
polyT, ribosomal RNAs, tRNAs, LINE, SINE, LTR and satellite
repeats, rRNA, scRNA and snRNAs, as well as adaptor, barcode,
and primer sequences. In our experiments, most reads filtered to
ribosomal RNAs and merged adaptor-barcode-primer sequences.
When aligning reads to the genome, two mismatches were allowed
on the seed, and alignments were extended when possible based
on a dynamic scoring function. The junction reference library was
generated from a list of known and putative exon-exon pairs
within RefSeq transcripts and contained approximately two
million fasta entries. Reverse reads in our experiments were
shorter than forward reads (25 vs 50, or 35 vs 75). To increase the
mapping rate for the shorter reverse reads, they were additionally
aligned to an ‘exon reference’ by allowing three mismatches on the
seed. This exon reference contained each known exon as a
separate reference entry. An exon rescue step was performed for
reads where one pair was mapped within a gene and its pair was
unaligned, by aligning the unmapped read within the downstream
exons of the same gene with up to six mismatches. The genome,
exon, junction, and rescued alignments were merged to generate a
single set of alignments for the forward and reverse tags separately.
Reads that aligned confidently to the filter reference were
subtracted from these alignments. A final pairing step was
performed to find most probable alignment pairs and assign a
pairing quality value (for formulas see Methods in Text S1). These
final paired alignments were put in a genome-coordinate BAM file
which represents the summary of mapped alignments except for
fusion alignments found by SASR.
Suffix Array Spliced Read (SASR) fusion finder
For reads that were admissible as a candidate to be spliced on a
fusion junction (see Methods in Text S1 for admission criteria), we
performed a suffix array search as follows. A read was defined to
provide evidence of a splice junction between an exon X and exon
Y if and only if (1) exon X maps to the prefix of the read, (2) exon
Y maps to the suffix of the read and (3) the sum of the two map
lengths is equal to the length of the read. For 50-bp long reads (or
49 colors plus a leading base), the suffix data structure was simply a
list (an array) of all suffixes of length 10 through 38 from all exons.
The suffixes were stored in lexicographically increasing order. A
string s=s 1s2…sm is lexicographically (i.e. alphabetically) less than
a string t=t 1t2…tn if s1,t1 or s1=t 1, and string s2s3…sm is
lexicographically less than string t2t3…tn. Each suffix was
represented compactly by a pair of integers (an integer and a
byte in the implementation): an index to the relevant exon in the
input exon list, and the length of the suffix. Such a data structure is
called a suffix array [60]. Because of the lexicographic order
proper, all suffixes that start with any given decamer were
consecutive in such a list. Therefore, one may quickly find all
matching suffixes with a binary search into the suffix array. Once
the list of exons that mapped to the prefix and suffix of the read
were identified, it could be determined whether the read provided
evidence for a unique junction.
Junction evidence graph and evaluation filters
A read was considered to be a SPAN evidence for a junction X-
Y between two exons if it was already junction mapped or if it was
discovered by SASR as described above. A paired-end read was
considered BRIDGE evidence for a junction X-Y if one read of
the pair mapped to exon X and the other mapped to exon Y with
PQV.10.
Candidate junctions were stored, each with a count of evidence,
number of unique start points and corresponding PQV, in a
sparse, directed graph. In this graph, exons corresponded to nodes,
and SPAN and BRIDGE evidences corresponded to two types of
edges between nodes. After all evidence was collected, junctions
were called by evaluating each candidate and assigning a junction
confidence value. At least one and two unique evidences of each
type were respectively required to call same-gene and different-
gene junctions (fusion). Exons could partially overlap, allowing for
junctions with different donor and acceptor sites to be counted as
alternative splices as long as at least two alternatives were detected.
Genes with overlapping annotations were not counted towards a
gene fusion if the evidence was ambiguous.
Paired-end RNA library preparation and sequencing
Human Breast Adenocarcinoma (MCF-7) Total RNA and
FirstChoiceH Human Brain Reference RNA (HBR) were obtained
from Ambion. Universal Human Reference Total RNA (UHR)
was obtained from Stratagene. Oligo(dT) selection was performed
twice by using MicroPoly(A)Purist
TM kit (Ambion) according to
the manufacturer’s recommendations. After polyA selection,
500 ng polyA RNA was fragmented using RNase III. 50 ng
fragmented RNA was then subjected to hybridization and ligation
using the SOLiD Total RNA-Seq Kit (Ambion) according to the
manufacturer’s instructions. Duplicate libraries, with three differ-
ent insert sizes (100–200 bp, 100–300 bp, 150–250 bp), were
generated from HBR and UHR RNAs. A total of 12 libraries were
multiplexed using the SOLiD RNA Barcoding Kit (Applied
Biosystems) and pooled at an equi-molar ratio. Two libraries were
made from same lot of MCF-7 polyA RNA with standard insert
size (100–200 bp). The final purified products were quantitated
using a NanoDropH instrument, and the size range of the products
was confirmed by Bioanalyzer
TM instrument analysis. The samples
were then diluted and used for emulsion PCR. Libraries were
sequenced utilizing 50 or 75 bp forward and 25 or 35 bp reverse
paired-end sequencing chemistry on the SOLiD system [47].
TaqMan real-time PCR assay validation
TaqMan probes and primers were designed for selected fusion
targets. For each putative fusion call, the target region for assay
design was composed of 200 bases around the fusion point: the
first 100 from the 59 gene exon and the second 100 from the 39
gene exon. If either of the exons was smaller than 100 bases, the
entire exon was taken but no bases from a further exon were used.
Therefore, any target region had a maximum of 200 bases. These
target sequences were then used to select TaqMan assay probes
RNA-Seq Mapping and Detection of Gene Fusions
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assays were used to validate the novel fusion candidates in
Universal Human Reference RNA sample (Stratagene), MCF-7
RNA (Ambion), Human Brain Reference RNA (Ambion), and a
no template control sample. cDNAs were generated from 2.5 ug
total RNA from each sample using the High Capacity cDNA
Archive Kit and protocol (Applied Biosystems). The resulting
cDNA products were diluted twenty-fold and four replicates were
run for each gene for each sample in a 384-well format plate on
7900HT Fast Real-Time PCR System (Applied Biosystems).
Cancer cell line and breast cancer clinical sample
screening
24 selected fusion targets (Figure 6) were screened across 20
cancer cell line RNAs and negative template control (NTC, Table
S5 in Text S2) using TaqMan probe and primers. Real-time PCR
reactions were run as described above. The same selected 24
fusion targets were also screened in 48 breast cancer clinical
samples (Origene) using TaqMan probe and primers. cDNAs were
generated from 2 ng total RNA from each sample using the High
Capacity cDNA Archive Kit and protocol (Applied Biosystems).
The resulting cDNA was subjected to a 16-cycle PCR amplifica-
tion followed by real-time PCR reaction using the manufacturer’s
TaqMan PreAmp Master Mix Kit Protocol (Applied Biosystems).
Preamplifed cDNA products were diluted twentyfold and four
replicates were run for each gene for each sample in a 384-well
plate on a 7900HT Fast Real-Time PCR System (Applied
Biosystems).
Supporting Information
Text S1 Supporting Methods and Figures. This text
contains additional methods and figures in support of the main
manuscript.
(DOCX)
Test S2 Supporting Tables. This table contains supplemen-
tary tables supplied as multiple worksheets in support of the main
manuscript.
(XLS)
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